Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
APONVIE | Heron Therapeutics | N-216457 RX | 2022-09-16 | 1 products, RLD, RS |
CINVANTI | Heron Therapeutics | N-209296 RX | 2017-11-09 | 1 products, RLD, RS |
EMEND | Merck & Co | N-021549 RX | 2003-03-26 | 2 products, RLD, RS |
EMEND | Merck & Co | N-207865 RX | 2015-12-17 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
aprepitant aprepitant | ANDA | 2025-06-13 |
emend | New Drug Application | 2022-05-04 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Aprepitant, Aponvie, Heron Theraps Inc | |||
9561229 | 2035-09-18 | DP | U-2161, U-3440 |
9808465 | 2035-09-18 | U-2161, U-3440 | |
9974742 | 2035-09-18 | DP | |
9974793 | 2035-09-18 | DP | |
9974794 | 2035-09-18 | DP | U-2161, U-3440 |
10500208 | 2035-09-18 | DP | |
10624850 | 2035-09-18 | U-2161, U-3440 | |
10953018 | 2035-09-18 | U-2161, U-3440 | |
11173118 | 2035-09-18 | DP | |
Aprepitant, Emend, Merck | |||
8258132 | 2027-09-26 | DP | U-901, U-1743, U-1916 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | — | R11.1 | 5 | 12 | 11 | 11 | 5 | 44 |
Nausea | D009325 | — | R11.0 | 1 | 10 | 10 | 9 | 5 | 35 |
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 2 | 3 | 3 | 3 | 13 |
Lymphoma | D008223 | — | C85.9 | — | — | — | 1 | 2 | 3 |
Leukemia | D007938 | — | C95 | — | 2 | — | 1 | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | 2 | — | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | 1 | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | — | — | 1 | — | 2 |
Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | 9 | — | — | 9 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | — | — | 9 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 9 | — | — | 9 |
Germ cell and embryonal neoplasms | D009373 | — | — | — | 1 | 1 | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | 1 | — | — | 2 |
Plasma cell neoplasms | D054219 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | — | 2 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Bile duct neoplasms | D001650 | — | — | — | 1 | — | — | — | 1 |
Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Sarcoma | D012509 | — | — | — | — | — | — | 1 | 1 |
Narcotic-related disorders | D000079524 | — | — | — | — | — | — | 1 | 1 |
Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
Drug common name | Aprepitant |
INN | aprepitant |
Description | Aprepitant is a morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It has a role as an antidepressant, an antiemetic, a peripheral nervous system drug, a neurokinin-1 receptor antagonist and a substance P receptor antagonist. It is a member of triazoles, a member of morpholines, a cyclic acetal and a member of (trifluoromethyl)benzenes. |
Classification | Small molecule |
Drug class | tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
PDB | — |
CAS-ID | 170729-80-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1471 |
ChEBI ID | 499361 |
PubChem CID | 135413536 |
DrugBank | DB00673 |
UNII ID | 1NF15YR6UY (ChemIDplus, GSRS) |